Prolymphocytic leukemia

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This phase 2 trial compares ibrutinib alone versus ibrutinib plus rituximab in 66 patients with relapsed chronic lymphocytic leukemia (CLL). Ibrutinib blocks cancer growth enzymes, while rituximab helps the immune system attack cancer cells. The study aims to see if the combinati…

This study tests a new oral drug called acalabrutinib (ACP-196) in people with chronic lymphocytic leukemia (CLL) or related blood cancers that have not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink or control the cancer. About …

This Phase 2 trial tests the drug ibrutinib in 154 people with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL). Participants take ibrutinib pills daily for 28-day cycles. The main goal is to se…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…